Bone sarcoma survival statistics

Survival

Survive bone sarcoma for 10 or more years, 2009-2013, England

 

Age

Age that bone sarcoma survival is highest, 2009-2013, England

 

Improvement

Bone sarcoma survival in the England has not changed in the last 25 years

 

84% of men survive bone sarcoma for at least one year, and this is predicted to fall to 62% surviving for five years or more, as shown by age-standardised Open a glossary item net survival for patients diagnosed with bone sarcoma during 2009-2013 in England.[1] Survival for women is similar, with 81% surviving for one year or more, and 62% predicted to survive for at least five years.

Bone Sarcoma (C40-C41), Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-90), England, 2009-2013

1-Year Survival (%) 5-Year Survival (%) 10-Year Survival (%)
Men Net Survival 83.7 61.8 55.0
95% LCL 81.4 58.7 50.6
95% UCL 85.7 64.8 59.2
Women Net Survival 81.2 61.5 53.8
95% LCL 78.3 57.8 48.9
95% UCL 83.7 65.0 58.4
Adults Net Survival 82.7 61.7 54.5
95% LCL 80.9 59.3 51.2
95% UCL 84.3 64.0 57.6

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item
 
Five- and ten-year survival is predicted using an excess hazard statistical model
 

Bone sarcoma survival is similar at five and ten years after diagnosis. 55% of men and 54% of women are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with bone sarcoma during 2009-2013 in England.[1]

References

  1. Muller P, Belot A, Morris M, Rachet B, Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine. Net survival and the probability of cancer death from rare cancers. Available from http://csg.lshtm.ac.uk/rare-cancers/. Accessed July 2016.
Last reviewed:

Five-year survival for bone sarcoma is highest in younger men and women and decreases with increasing age. Five-year net survival in men ranges from 71% in 50-59 year-olds to 44% in 70-89 year-olds for patients diagnosed with bone sarcoma in England during 2009-2013.[1] In women, five-year survival ranges from 75% in 15-49 year olds to 38% in70-89 year olds.

Bone Sarcoma (C40, C41), Five-Year Net Survival by Age, England, 2009-2013

References

  1. Muller P, Belot A, Morris M, Rachet B, Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine. Net survival and the probability of cancer death from rare cancers. Available from http://csg.lshtm.ac.uk/rare-cancers/. Accessed July 2016.
Last reviewed:

Five-year relative survival for bone sarcoma in men in England (50%) is similar to the average for Europe (50%). Northern Ireland (58%) is also similar to the European average but Scotland (30%) is below the European average.[1] No five-year survival data is available for Wales. Across the European countries for which data is available, five-year relative survival in men ranges from 27% (Bulgaria) to 74% (Switzerland).[1

Five-year relative survival for bone sarcoma in women in England (52%) is similar to the average for Europe (56%). Wales (60%) and Northern Ireland (65%) are also  similar to the European average but Scotland (36%) is below the European average.[1] Across the European countries for which data is available, five-year relative survival in women ranges from 35% (Latvia) to 73% (The Netherlands).[1]

Bone sarcoma (C40-C41), Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, bone and cartilage cancer (International Classification of Diseases for Oncology [ICD-O-3] C40-C41).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Rate this page:

Currently rated: 1.5 out of 5 based on 8 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page